What is the mechanism of action of Pluvicto in the context of prostate cancer?

Hi,

Welcome to icliniq.com.

I understand your concern.

Pluvicto (Lutetium vipivotide tetraxetan) is a radiopharmaceutical agent. On prostate cancer cells, there is a receptor called PSMA. The drug binds to it and gets inside the cell, releasing radiation that kills the cancer cells. Its use involves exposure to radioactivity. Long-term radiation exposure can increase the risk of cancer. To minimize radiation exposure to others following drug administration, limit close contact (less than three feet) with household contacts for two days or with children and pregnant women for seven days, refrain from sexual activity for seven days, and sleep in a separate bedroom from household contacts for three days, from children for seven days, or from pregnant women for 15 days.

I hope this information will help you.

Thanks.